Drug development company Evgen Pharma said it has “achieved a great deal” in recent months in the research and operational sides of the business.
Evgen, which operates from Wilmslow and Liverpool, develops medicines with a focus on cancer and respiratory diseases.
Dr Huw Jones, who joined as chief executive in October, said: “Substantial progress was made in the half year in business development and in particular in our STAR trial where patients with community acquired pneumonia from any infection including Covid-19 can be recruited.”
He said “preliminary pre-clinical data look compelling” for its next cancer indication as the company continues “to demonstrate the huge potential of our pipeline”.
Evgen’s core technology is Sulforadex, a method for synthesising and stabilising the naturally-occurring compound sulforaphane and novel proprietary analogues based on sulforaphane.
Its lead product, SFX-01, has has been used to treat over 150 patients in clinical trials for advanced metastatic breast cancer.
The business recorded a £1.8m loss in the six months to September, which it said was in line with expectations, and had £2.3m cash at the end of the period.
In September it revealed it had agreed a licensing deal worth an initial £8m with biotech incubator Juvenescence. The payments are based on milestones, with royalties on sales, and the product is expected to be launched in two years’ time.
To access the article, please click here.